Vepdegestrant Results in Longer PFS Than Fulvestrant in Previously Treated Patients with ESR1-mutated, ER-positive, HER2-negative ABC By Ogkologos - June 4, 2025 682 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the VERITAC-2 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer June 30, 2025 Home Is Where the Heart Is November 8, 2019 Long-Term Outcomes Suggest a Sustained Clinical Benefit to Metastasis-Directed Treatment Over... August 31, 2022 Holidays, Traditions and Grief December 21, 2020 Load more HOT NEWS High Response Rates Observed Following KTE-X19 CAR T-Cell Therapy in Adults... Advances in Gynaecological Cancer Research Could Change the Treatment Landscape Hormone Therapy Can Put Cancer Cells Into Sleep Mode And Cause... Adding Checkpoint Inhibition to Anti-HER2 Breast Cancer Therapy Brings no Benefit...
